They were investigated for a composite endpoint including recurrent angina, non-fatal MI, target vessel revascularization, heart failure and cardiac death.
The primary aim of the analysis was to compare outcomes by stent type for death, myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis in randomized trials of ST-segment elevation myocardial infarction (STEMI).
Secondary outcomes were MI, target lesion revascularization (TLR), and stent thrombosis (ST).
Outcome measurements were death, myocardial infarction (MI), target lesion revascularisation (TLR), binary definition of restenosis and in-lesion late luminal loss (LLL).
I don't know if all the color options, or stores, are running the same pricing, but at least the red and blue models are $25 at Flint, MI target.
All-cause mortality was selected as the primary end point while recurrent myocardial infarction (re-MI), target vessel revascularization (TVR) and major bleeding complications were the secondary end points.
Study end-points were all-cause death, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST) and the composite of major adverse cardiovascular events (MACE), defined as death, MI or TVR.
In the study by Di Serafino et al, MACCE was defined as the composite of all-cause death, non-fatal MI, target vessel failure, and cerebrovascular accidents.
The endpoint of this study was major adverse coronary and cerebral events, defined as cardiac death, non-fatal MI, target vessel revascularization, and cerebral artery events.
The overall major adverse coronary and cerebral events (22.6% versus 20.1% in men and women, respectively, P=0.984), including cardiac death, non-fatal acute MI, target vessel revascularization and cerebral vascular events, showed no significant difference.
The values of 0.5 to 1 or −0.5 to −1 were considered to be slight mis-targeting, and those greater than 1 or less than −1 to be substantially mis-targeting [ 31].
